{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:39:06Z","timestamp":1793662746007,"version":"4.5.1"},"reference-count":95,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1053\/j.semnuclmed.2025.09.003","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T15:43:50Z","timestamp":1758987830000},"page":"912-927","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Nectin-4, Bladder Cancer, and Nuclear Medicine: A Theranostic Frontier"],"prefix":"10.1053","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5537-2746","authenticated-orcid":false,"given":"Joseph","family":"Kabunda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-8995","authenticated-orcid":false,"given":"Honest","family":"Ndlovu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1734-1768","authenticated-orcid":false,"given":"Karishma","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandile","family":"Sibiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sipho","family":"Mdanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamo","family":"Ramonaheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0978-4716","authenticated-orcid":false,"given":"Akram","family":"Al-Ibraheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kgomotso","family":"Mokoala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2806-0625","authenticated-orcid":false,"given":"Mike","family":"Sathekge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0001","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020411","article-title":"Immune-checkpoint inhibitors in advanced bladder cancer: Seize the day","volume":"10","author":"Maiorano","year":"2022","journal-title":"Biomedicines"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0002","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1471-2407-7-73","article-title":"Nectin-4 is a new histological and serological tumor associated marker for breast cancer","volume":"7","author":"Fabre-Lafay","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0003","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","article-title":"Expression of nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes","volume":"29","author":"Hoffman-Censits","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0004","article-title":"Nectin-4 positivity in genitourinary malignancies: A systematic review","volume":"8","author":"Crupi","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0005","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1158\/1535-7163.MCT-21-0846","article-title":"The anti-nectin 4: A promising tumor cells target. A systematic review","volume":"21","author":"Bouleftour","year":"2022","journal-title":"Mol Cancer Therap"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0006","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1158\/1078-0432.CCR-23-3738","article-title":"FDA approval summary: Enfortumab Vedotin plus Pembrolizumab for cisplatin-ineligible locally advanced or metastatic urothelial carcinoma","volume":"30","author":"Maguire","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0007","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/cncr.34057","article-title":"Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study","volume":"128","author":"Koshkin","year":"2022","journal-title":"Cancer."},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0008","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab Vedotin plus Pembrolizumab in previously untreated advanced urothelial cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0009","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/CU9.0000000000000204","article-title":"Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review","volume":"17","author":"Bantounou","year":"2023","journal-title":"Curr Urol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0010","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with Enfortumab Vedotin resistance","volume":"29","author":"Kl\u00fcmper","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14737140.2023.2288140","article-title":"NECTIN-4 targeted theranostics for urothelial cancer: Getting ready for primetime?","volume":"24","author":"Filippi","year":"2024","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0012","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1148\/radiol.2019190032","article-title":"Delayed (18)F FDG PET\/CT imaging in the assessment of residual tumors after transurethral resection of bladder cancer","volume":"293","author":"Yan","year":"2019","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0013","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cpet.2015.07.005","article-title":"Diuretic 18F-fluorodeoxyglucose PET\/computed tomography in evaluation of genitourinary malignancies","volume":"11","author":"Agarwal","year":"2016","journal-title":"PET Clin"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0014","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1016\/j.jacr.2018.03.020","article-title":"ACR appropriateness criteria(\u00ae) pretreatment staging of muscle-invasive bladder cancer","volume":"15","author":"van der Pol","year":"2018","journal-title":"J Am Coll Radiol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0015","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00345-016-1772-z","article-title":"The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: A single-institution study and a systematic review with meta-analysis","volume":"34","author":"Soubra","year":"2016","journal-title":"World J Urol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0016","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s43046-023-00180-5","article-title":"Fluorodeoxyglucose positron emission tomography (18F-FDG PET)-computed tomography (CT) in the initial staging of bladder cancer: A single institution experience","volume":"35","author":"Shahait","year":"2023","journal-title":"J Egyptian Natl Cancer Inst"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0017","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s12672-025-03020-1","article-title":"Diagnostic efficacy of [18F]FDG PET\/CT and [18F]FDG PET\/MRI in preoperative staging of locoregional urinary bladder cancer: A systematic review and meta-analysis","volume":"16","author":"Abdlkadir","year":"2025","journal-title":"Discov Oncol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17020232","article-title":"Nuclear medicine and molecular imaging in urothelial cancer: Current status and future directions","volume":"17","author":"McDonald","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0019","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s11307-022-01715-3","article-title":"Head-to-head intra-individual comparison of [68Ga]-FAPI and [18F]-FDG PET\/CT in patients with bladder cancer","volume":"24","author":"Novruzov","year":"2022","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0020","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12894-022-01074-9","article-title":"Expression and prognostic value of carbonic anhydrase IX (CA-IX) in bladder urothelial carcinoma","volume":"22","author":"Xiang","year":"2022","journal-title":"BMC Urol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135824","article-title":"uPAR expression pattern in patients with urothelial carcinoma of the bladder\u2013possible clinical implications","volume":"10","author":"Dohn","year":"2015","journal-title":"PLoS One"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0022","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1158\/1078-0432.CCR-23-1243","article-title":"PET imaging of Nectin-4: A promising tool for personalized\/precision oncology","volume":"29","author":"Jiang","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0023","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2967\/jnumed.121.262997","article-title":"The history of Prostate-specific membrane antigen as a theranostic target in Prostate Cancer: The cornerstone role of the Prostate Cancer Foundation","volume":"63","author":"Miyahira","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114539","volume":"211","author":"Sathekge","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0025","doi-asserted-by":"crossref","first-page":"43205","DOI":"10.1074\/jbc.M103810200","article-title":"Nectin4\/PRR4, a new afadin-associated member of the nectin family that trans-interacts with nectin1\/PRR1 through V domain interaction","volume":"276","author":"Reymond","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0026","doi-asserted-by":"crossref","first-page":"19543","DOI":"10.1074\/jbc.M410943200","article-title":"Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)\/ADAM-17","volume":"280","author":"Fabre-Lafay","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0027","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00358","article-title":"A role for PVRL4-driven cell-cell interactions in tumorigenesis","volume":"2","author":"Pavlova","year":"2013","journal-title":"Elife"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0028","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.biocel.2018.07.011","article-title":"The soluble nectin-4 ecto-domain promotes breast cancer induced angiogenesis via endothelial integrin-\u03b24","volume":"102","author":"Siddharth","year":"2018","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0029","article-title":"Therapeutic prospects of nectin-4 in cancer: Applications and value","volume":"14","author":"Li","year":"2024","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0030","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/14712598.2021.1929168","article-title":"Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma","volume":"21","author":"Wong","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0031","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and Carcinoma In Situ) - 2019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0032","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab Vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0033","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/annonc\/mdw678","article-title":"Nectin-4: A new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer","volume":"28","author":"MR","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0034","article-title":"Prognostic value of nectin-4 in human cancers: A meta-analysis","volume":"13","author":"Liu","year":"2023","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0035","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/MOU.0000000000000641","article-title":"Clinical implications of molecular subtyping in bladder cancer","volume":"29","author":"Satyal","year":"2019","journal-title":"Curr Opin Urol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0036","first-page":"9743","article-title":"Assessment of luminal and basal phenotypes in bladder","volume":"10","author":"Guo","year":"2020","journal-title":"Cancer. Sci Rep."},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0037","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: A phase I study of single-agent Enfortumab Vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0038","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","article-title":"EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma","volume":"34","author":"Rosenberg","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0039","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"New Engl J Med"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0040","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1200\/JCO.2024.42.4_suppl.622","article-title":"Phase 1 dose escalation of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate (ADC)","volume":"42","author":"Ye","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0041","first-page":"TPS898","article-title":"A phase 2\/3 study of bicycle toxin conjugate zelenectide pevedotin (BT8009) targeting Nectin-4 in patients with locally advanced or metastatic urothelial cancer (la\/mUC) (Duravelo-2)","volume":"43","author":"Loriot","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0042","doi-asserted-by":"crossref","first-page":"CT084","DOI":"10.1158\/1538-7445.AM2024-CT084","article-title":"Abstract CT084: A phase 1 study of LY4101174 (ETx-22), an antibody-drug conjugate targeting nectin-4, in patients with advanced or metastatic urothelial cancer and other solid tumors (trial in progress)","volume":"84","author":"Rosenberg","year":"2024","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0043","first-page":"TPS900","article-title":"NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors","volume":"43","author":"Gao","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0044","article-title":"Development of Nectin4\/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2024.111351","article-title":"Potential cellular intravesical therapy for non-muscle invasive bladder cancer: Nectin-4 targeted CAR-T cell therapy","volume":"187","author":"Alt\u0131nta\u015f","year":"2024","journal-title":"Med Hypothes"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0046","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.2217\/fon-2022-0328","article-title":"Enfortumab vedotin in the treatment of urothelial cancers and beyond","volume":"18","author":"Wong","year":"2022","journal-title":"Future Oncol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0047","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","article-title":"Management of dermatologic events associated with the Nectin-4-directed antibody-drug conjugate Enfortumab Vedotin","volume":"27","author":"Lacouture","year":"2022","journal-title":"Oncologist"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0048","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/iju.15109","article-title":"Chemotherapy with gemcitabine and cisplatin downregulates tumor expression level of nectin-4 in a syngeneic model of murine MBT2 urothelial cancer cell line and C3H mice","volume":"30","author":"Miyake","year":"2023","journal-title":"Int J Urol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0049","unstructured":"Lopez M. Antibodies having specificity to nectin-4 and uses thereof. December 12, 2025, 2025.https:\/\/patents.google.com\/patent\/WO2018158398A1\/en"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0050","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1158\/1078-0432.CCR-23-0609","article-title":"First-in-Human study of the Radioligand 68Ga-N188 targeting nectin-4 for PET\/CT imaging of advanced urothelial carcinoma","volume":"29","author":"Duan","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0051","doi-asserted-by":"crossref","first-page":"764","DOI":"10.2967\/jnumed.106.036350","article-title":"18F-FDG PET\/CT delayed images after diuretic for restaging invasive bladder cancer","volume":"48","author":"Anjos","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0052","doi-asserted-by":"crossref","first-page":"12s","DOI":"10.2967\/jnumed.123.266830","article-title":"Translational PET imaging of nectin-4 expression in multiple different cancers with (68)Ga-N188","volume":"65","author":"Zhang","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0053","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s11307-016-0953-x","article-title":"Preclinical evaluation of an anti-nectin-4 ImmunoPET reagent in tumor-bearing mice and biodistribution studies in Cynomolgus monkeys","volume":"18","author":"Campbell","year":"2016","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0054","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12951-022-01444-3","article-title":"Nectin-4-targeted immunoSPECT\/CT imaging and photothermal therapy of triple-negative breast cancer","volume":"20","author":"Shao","year":"2022","journal-title":"J Nanobiotechnol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0055","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1254906","article-title":"Enfortumab vedotin in metastatic urothelial carcinoma: The solution EVentually?","volume":"13","author":"Maiorano","year":"2023","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0056","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2967\/jnumed.124.268387","article-title":"225Ac\/89Zr-Labeled N4MU01 Radioimmunoconjugates as theranostics against nectin-4 positive triple negative breast cancer","volume":"66","author":"Babeker","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0057","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1208\/s12248-009-9157-5","article-title":"Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease","volume":"12","author":"Tabrizi","year":"2010","journal-title":"Aaps J"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114539","volume":"211","author":"Sathekge","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0059","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumor imaging: Version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0060","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/jlcr.3612","article-title":"Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapy-model, vector, and radionuclide selection","volume":"61","author":"Carter","year":"2018","journal-title":"J Labelled Comp Radiopharm"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0061","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2174\/18744710113066660023","article-title":"Targeted radionuclide therapy: An overview","volume":"6","author":"Dash","year":"2013","journal-title":"Curr Radiopharm"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0062","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2967\/jnumed.124.269215","article-title":"Consensus nomenclature for radionuclide therapy: Initial recommendations from Nuclear Medicine Global Initiative","volume":"66","author":"Al-Ibraheem","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0063","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153904","article-title":"PSMA Theranostics: Science and practice","volume":"13","author":"Mokoala","year":"2021","journal-title":"Cancers (Basel)."},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0064","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11080424","article-title":"Therapeutic Potential of 47Sc in Comparison to 177Lu and 90Y: Preclinical investigations","volume":"11","author":"Siwowska","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0065","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119154","article-title":"Recent advances in (64)Cu\/(67)Cu-based radiopharmaceuticals","volume":"24","author":"Krasnovskaya","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0066","article-title":"Targeted thorium-227 conjugates as treatment options in oncology","volume":"9","author":"Karlsson","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0067","article-title":"Astatine-211 based radionuclide therapy: Current clinical trial landscape","volume":"9","author":"Albertsson","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0068","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.2967\/jnumed.124.268101","article-title":"Preclinical investigation of [(212)Pb]Pb-DOTAM-GRPR1 for peptide receptor radionuclide therapy in a prostate tumor model","volume":"65","author":"Saidi","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0069","unstructured":"Wang H. 18F-LN1 PET\/CT in urothelial carcinomas. 2025. https:\/\/clinicaltrials.gov\/study\/NCT06120413. Accessed April 5, 2025."},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0071","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1158\/1535-7163.MCT-21-0875","article-title":"BT8009; A nectin-4 targeting bicycle toxin conjugate for treatment of solid tumors","volume":"21","author":"Rigby","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0072","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2024.03.013","article-title":"Activity of Enfortumab Vedotin and Sacituzumab Govitecan with radiation in preclinical models of bladder cancer","volume":"86","author":"Zhou","year":"2024","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0073","unstructured":"NIH. Enfortumab Vedotin with concurrent radiation therapy for the treatment of locally advanced bladder cancer, CONSOLIDATE trial. https:\/\/www.cancer.gov\/research\/participate\/clinical-trials-search\/NCI-2024-04592. (accessed March 2, 2025)."},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0074","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1158\/1078-0432.CCR-21-4332","article-title":"Combining targeted radionuclide therapy and immune checkpoint inhibition for cancer treatment","volume":"28","author":"Kleinendorst","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0075","doi-asserted-by":"crossref","first-page":"7948","DOI":"10.7150\/thno.39203","article-title":"Integrin \u03b1(v)\u03b2(3)-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy","volume":"9","author":"Chen","year":"2019","journal-title":"Theranostics"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0076","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb3631","article-title":"Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade","volume":"13","author":"Patel","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0077","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1158\/1078-0432.CCR-11-3201","article-title":"Phase I study of vincristine, irinotecan, and \u00b9\u00b3\u00b9I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: A new approaches to neuroblastoma therapy trial","volume":"18","author":"DuBois","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0078","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1038\/s41598-022-07727-x","article-title":"Nectin cell adhesion molecule 4 regulates angiogenesis through Src signaling and serves as a novel therapeutic target in angiosarcoma","volume":"12","author":"Tanaka","year":"2022","journal-title":"Scient Rep"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0079","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.858865","article-title":"Head-to-Head comparison of the expression differences of NECTIN-4, TROP-2, and HER2 in urothelial carcinoma and its histologic variants","volume":"12","author":"Fan","year":"2022","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0080","doi-asserted-by":"crossref","DOI":"10.3389\/fddev.2024.1339936","article-title":"Future theranostic strategies: Emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment","volume":"4","author":"Rajapaksha","year":"2024","journal-title":"Front Drug Deliv"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0081","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1158\/0008-5472.CAN-09-0016","article-title":"Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer","volume":"69","author":"Takano","year":"2009","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0082","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4161\/mabs.4.2.19000","article-title":"Dual targeting strategies with bispecific antibodies","volume":"4","author":"Kontermann","year":"2012","journal-title":"MAbs"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0083","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/blood-2017-09-807610","article-title":"CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies","volume":"131","author":"Green","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0084","article-title":"Theranostic polymeric nanoparticles as a new approach in cancer therapy and diagnosis: A review","volume":"29","author":"Hosseini","year":"2023","journal-title":"Mater Today Chemistry"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0085","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.2967\/jnumed.114.146019","article-title":"Theranostic nanoparticles","volume":"55","author":"Chen","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0086","doi-asserted-by":"crossref","first-page":"5829","DOI":"10.1007\/s00330-024-10637-3","article-title":"Artificial intelligence in immunotherapy PET\/SPECT imaging","volume":"34","author":"McGale","year":"2024","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0087","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005292","article-title":"Artificial intelligence and radiomics: Fundamentals, applications, and challenges in immunotherapy","volume":"10","author":"Dercle","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0088","first-page":"33","article-title":"Advancing precision medicine: The transformative role of artificial intelligence in immunogenomics, radiomics, and pathomics for biomarker discovery and immunotherapy optimization","volume":"22","author":"Chang","year":"2025","journal-title":"Cancer Biol Med"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0089","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.3390\/pharmaceutics15061733","article-title":"Clinical advances and perspectives in targeted radionuclide therapy","volume":"15","author":"Lepareur","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0090","unstructured":"Yu E. Nectin-4, A validated target for urothelial cancer; opening the door for novel imaging and therapeutic development. Urol Today.https:\/\/www.urotoday.com\/clinical-trials\/from-the-editor\/157875-nectin-4-a-validated-target-for-urothelial-cancer-opening-the-door-for-novel-imaging-and-therapeutic-development.html"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0091","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0092","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.3390\/cancers16111974","article-title":"From despair to hope: First Arabic experience of 177Lu-PSMA and 161Tb-PSMA therapy for metastatic castration-resistant prostate cancer","volume":"16","author":"Al-Ibraheem","year":"2024","journal-title":"Cancers"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0093","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of Enfortumab Vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0094","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV\u2011201): A multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0095","article-title":"Nectin-4 pet for optimizing enfortumab vedotin dose-response in urothelial carcinoma","author":"Mishra","year":"2024","journal-title":"bioRxiv [Preprint]"},{"key":"10.1053\/j.semnuclmed.2025.09.003_bib0096","doi-asserted-by":"crossref","first-page":"TPS589","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS589","article-title":"Study EV-302: A two-arm, open-label, randomized controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated advanced urothelial carcinoma (aUC) (trial in progress)","volume":"40","author":"Van Der Heijden","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825001187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825001187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T21:46:52Z","timestamp":1761428812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299825001187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":95,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0001299825001187"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.09.003","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nectin-4, Bladder Cancer, and Nuclear Medicine: A Theranostic Frontier","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}